Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Shira Hughes

Nurse Practitioner Morgantown, KY Nurse Practitioner

NPI 1104238146 CMS profile 10559160

234 Porter St, Morgantown, KY 42261

Open in the dashboard

General payments

$2,793

176 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shira Hughes of Morgantown, KY is reported in the CMS Open Payments database as having received $2,793 across 176 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $645 41
2024 General $766 46
2023 General $438 25
2022 General $456 31
2021 General $488 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shira Hughes
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Shira Hughes were reported at $645. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Shira Hughes Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $488 $135 $40–$426 $132
2022 $456 $152 $48–$470 $149
2023 $438 $166 $54–$529 $160
2024 $766 $173 $55–$556 $164
2025 $645 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Amgen Inc. $449 31 payments
  2. GlaxoSmithKline, LLC. $324 19 payments
  3. Pfizer Inc. $206 12 payments
  4. Novo Nordisk Inc $163 11 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $153 9 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $138 9 payments
  7. Exact Sciences Corporation $115 8 payments
  8. AbbVie, Inc. $103 6 payments
  9. AstraZeneca Pharmaceuticals LP $79 6 payments
  10. Kowa Pharmaceuticals America, Inc. $76 5 payments
  11. Other $988 60 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,793 176 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $295 17 payments
  2. Repatha Cardiology $245 16 payments
  3. ELIQUIS $189 11 payments
  4. Otezla $167 12 payments
  5. REPATHA Cardiovascular $163 12 payments
  6. XIFAXAN $153 9 payments
  7. AREXVY $143 9 payments
  8. Kerendia $138 9 payments
  9. NURTEC ODT $126 7 payments
  10. Cologuard Collection Kit $115 8 payments
  11. Other $1,790 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 108 drugs

Part D claims

4,893

Median for Nurse Practitioner: 389

Drug cost

$511,426

Median for Nurse Practitioner: $21,885

Branded share of claims

24.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 83 $87,764
Eliquis Apixaban Brand 52 $52,017
Mounjaro Tirzepatide Brand 42 $48,703
Jardiance Empagliflozin Brand 38 $40,160
Januvia Sitagliptin Phosphate Brand 34 $37,843
Linzess Linaclotide Brand 45 $35,160
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 38 $28,711
Tresiba Flextouch U-200 Insulin Degludec Brand 12 $27,556
Rexulti Brexpiprazole Brand 15 $25,169
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 25 $15,759

The 10 drugs with the highest cost, of 108 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$22,132

Of which drugs: $208

Medicare patients

127

Average age 70

Services billed

1,003

72 women, 55 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 45%
Arthritis 43%
Depression 39%
Ischemic heart disease 34%
Chronic kidney disease 28%
Osteoporosis 28%
Heart failure 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 24 104 $70
Injection, ceftriaxone sodium, per 250 mg J0696 Office 25 136 $43
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 15 18 $16

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $108
$108 38 —
AREXVY
  • GlaxoSmithKline, LLC. $69
$69 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $44
  • Lundbeck LLC $24
$68 15 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $64
$64 — —
Repatha
  • Amgen Inc. $57
$57 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

176 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record